文献速递淋巴瘤

基于英格兰公共卫生数据的维布妥昔单抗治疗复发系统性间变性大细胞淋巴瘤的疗效:一项基于人群的队列研究

Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
PubMed 文献 · Br J Haematol · 2021-10-18

本研究利用英格兰公共卫生数据,纳入2014至2019年接受维布妥昔单抗单药治疗的127例复发/难治系统性间变性大细胞淋巴瘤成人患者。真实世界生存结果与既往临床试验数据相当。

要点

  • ALK状态、年龄、性别及一线是否接受移植对OS无显著影响。

核心结论

  • 真实世界中维布妥昔单抗治疗复发/难治sALCL的生存结果与既往临床试验数据相当。

研究设计与样本

  • 基于英格兰公共卫生数据的基于人群的队列研究。
  • 纳入2014年1月1日至2019年12月31日在英格兰接受维布妥昔单抗单药治疗的127例≥18岁复发/难治sALCL患者。

主要发现

  • 绝大多数死亡(59例)发生在18个月内,此后事件极少。
  • 不同亚组包括ALK状态、年龄、性别或一线缓解期是否接受干细胞移植,OS无差异。

临床怎么用

  • 对于复发/难治sALCL成人患者,维布妥昔单抗单药治疗可获得与临床试验一致的生存获益。
  • 尽早在一线治疗失败后二线使用维布妥昔单抗可能改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic anaplastic large-cell lymphoma (sALCL) is a rare T-cell lymphoma associated with poor prognosis after relapse. The immunoconjugate brentuximab vedotin (BV) first became available for relapsed sALCL in England in 2013, following the results of a pivotal phase II study. We present a population-based study describing outcomes of relapsed sALCL in England after BV, using Public Health England data. We obtained information on all relapsed/refractory (r/r) sALCL patients ≥18 years treated with BV monotherapy in England between 1 January 2014 and 31 December 2019. The final cohort comprised 127 patients with a median age of 60 years (range 19-89). Eighteen (14·2%) had received stem cell transplant in first remission. Median two-year overall survival (OS) was 46·6%. The vast majority of deaths (59) occurred within 18 months, with very few events after this. Receipt of BV as second line compared to third or fourth line was associated with significantly improved survival (two-year OS 50·3% vs 29·7%, P = 0·03). There was no difference in OS for different subgroups, including anaplastic lymphoma kinase status, age, gender, or receipt of stem cell transplantation in first response. We report excellent survival following treatment with BV in a real-world setting, comparable with previous clinical trial data.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Halligan SJ, Grainge MJ, Martinez-Calle N, et al. Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data. Br J Haematol. 2021. PMID: 34664265. doi:10.1111/bjh.17896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。